| LymphoCide Y-90 (epratuzumab Y-90) / Gilead |
2007-002414-19: Etude prospective multicentrique de phase II évaluant la radioimmunothérapie fractionnée avec un anticorps humanisé anti-CD22 marqué à l\'yttrium 90 (90Y-DOTA-hLL2) en consolidation après immuno-chimiothérapie R-CHOP dans les lymphomes B agressifs disséminés du sujet de plus de 60 ans |
|
|
| Ongoing | 2 | 75 | Europe | IgG1 anti-cellule B hLL2 marqué à l\' Ytrium 90, IgG1 anti-celluleB hLL2, 90 Y-DOTA-hLL2, hLL2 IgG, | GOELAMS | lymphomes B agressifs disséminés du sujet de plus de 60 ans et de moins de 80 ans. | | | | |
NCT00906841: Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma |
|
|
| Terminated | 2 | 75 | Europe | 90Y-DOTA-hLL2, consolidation | French Innovative Leukemia Organisation | B-cell Lymphoma | 03/16 | 04/18 | | |
RITEPRALL, NCT02844530: Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL |
|
|
| Withdrawn | 2 | 0 | Europe | 90Y-epratuzumab tetraxetan, 90Y-DOTA-hLL2 or 90Y-DOTA-Epratuzumab, chemotherapy/ immunotherapy | Nantes University Hospital | CD22+ Relapsed/Refractory B-ALL | 01/17 | 01/17 | | |
NCT00004107: Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia |
|
|
| Completed | 1/2 | 18 | US | filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 epratuzumab | Garden State Cancer Center at the Center for Molecular Medicine and Immunology, National Cancer Institute (NCI) | Leukemia, Lymphoma | 05/01 | | | |
NCT00004084: Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia |
|
|
| Completed | 1/2 | 21 | US | indium In 111 LL2 IgG, yttrium Y 90 epratuzumab | Garden State Cancer Center at the Center for Molecular Medicine and Immunology, National Cancer Institute (NCI) | Leukemia, Lymphoma | 05/02 | | | |
| Completed | 1/2 | 59 | Europe | 90Y-hLL2, epratuzumab, hLL2 | Gilead Sciences | NHL, B-cell NHL, Non-Hodgkins Lymphoma | 10/07 | 10/07 | | |
NCT00061425: Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG |
|
|
| Completed | 1/2 | | NA | radiolabeled epratuzumab | Gilead Sciences | Non-Hodgkin's Lymphoma, Lymphoma, B-Cell | 11/07 | | | |
NCT00670592 / 2007-004888-22: Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies |
|
|
| Completed | 1/2 | 111 | Europe, Canada, US, RoW | HCD122 | Novartis Pharmaceuticals, XOMA (US) LLC | Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma | 02/13 | 02/13 | | |
NCT01147393: Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma |
|
|
| Terminated | 1/2 | 4 | US | 90Y-epratuzumab tetraxetan, veltuzumab | Weill Medical College of Cornell University, Gilead Sciences | Follicular Lymphoma | 08/13 | 07/15 | | |
NCT01354457: Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+ |
|
|
| Unknown status | 1/2 | 21 | Europe | Epratuzumab and 90Y-Epratuzumab | Nantes University Hospital | Acute Lymphoblastic Leukemia | 06/16 | 06/16 | | |
|
|
NCT01101581: Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL |
|
|
| Withdrawn | 1/2 | 0 | US | Veltuzumab and 90Y-Epratuzumab Tetraxetan, veltuzumab, IMMU-106, hA20, humanized CD20, epratuzumab-tetraxetan, 90Y-hLL2, IMMU-102, humanized CD22, 90Y-epratuzumab tetraxetan, 90Y-hLL2-DOTA, 90Y-CD22 | Gilead Sciences | Non Hodgkin's Lymphoma, NHL, Aggressive NHL, Diffuse Large B-cell Lymphoma | 12/16 | 03/17 | | |
|
EPRALLO, NCT02577094: Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia |
|
|
| Withdrawn | 1/2 | 0 | NA | 90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG, 90Y-DOTA- hLL2 IgG and hLL2 IgG, Busulfan, allogeneic stem cell transplantation., Fludarabine, Thymoglobulines | Nantes University Hospital, Gilead Sciences, Institut Cancerologie de l'Ouest | Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia | 01/17 | 01/17 | | |
